Notice: This company has been marked as potentially delisted and may not be actively trading. Nightstar Therapeutics (NITE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NITE vs. DNLI, SRRK, IBRX, KYMR, SWTX, TWST, VCEL, IOVA, CGON, and BEAMShould you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Denali Therapeutics (DNLI), Scholar Rock (SRRK), ImmunityBio (IBRX), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Vericel (VCEL), Iovance Biotherapeutics (IOVA), CG Oncology (CGON), and Beam Therapeutics (BEAM). These companies are all part of the "medical" sector. Nightstar Therapeutics vs. Denali Therapeutics Scholar Rock ImmunityBio Kymera Therapeutics SpringWorks Therapeutics Twist Bioscience Vericel Iovance Biotherapeutics CG Oncology Beam Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Nightstar Therapeutics (NASDAQ:NITE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community favor DNLI or NITE? Denali Therapeutics received 225 more outperform votes than Nightstar Therapeutics when rated by MarketBeat users. However, 69.88% of users gave Nightstar Therapeutics an outperform vote while only 67.77% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes45067.77% Underperform Votes21432.23% Nightstar TherapeuticsOutperform Votes22569.88% Underperform Votes9730.12% Does the media favor DNLI or NITE? In the previous week, Denali Therapeutics had 10 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 10 mentions for Denali Therapeutics and 0 mentions for Nightstar Therapeutics. Denali Therapeutics' average media sentiment score of 1.57 beat Nightstar Therapeutics' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Denali Therapeutics Very Positive Nightstar Therapeutics Neutral Which has higher earnings and valuation, DNLI or NITE? Nightstar Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M10.40-$145.22M-$2.76-8.66Nightstar TherapeuticsN/AN/A-$36.86M-$1.26-23.55 Do analysts recommend DNLI or NITE? Denali Therapeutics currently has a consensus target price of $38.90, indicating a potential upside of 62.83%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Denali Therapeutics is more favorable than Nightstar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73Nightstar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in DNLI or NITE? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 32.8% of Nightstar Therapeutics shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, DNLI or NITE? Denali Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Nightstar Therapeutics has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500. Is DNLI or NITE more profitable? Nightstar Therapeutics' return on equity of -30.89% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% Nightstar Therapeutics N/A -30.89%-27.65% SummaryDenali Therapeutics beats Nightstar Therapeutics on 10 of the 16 factors compared between the two stocks. Ad InvestorPlaceThe Biggest Financial Event of 2024?Should you buy, sell, or hold your stock? To find the answer, let’s look at the actions of the world’s wealthiest investors… Right now, the world’s wealthiest investors are preparing for what could become ‘the biggest financial event’ of 2024.Click here for the step-by-step details Get Nightstar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NITE vs. The Competition Export to ExcelMetricNightstar TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$995.13M$3.05B$5.16B$9.02BDividend YieldN/A1.83%5.41%4.04%P/E Ratio-23.5516.1679.9513.31Price / SalesN/A303.731,361.4083.40Price / CashN/A175.9441.9338.46Price / Book5.043.984.894.92Net Income-$36.86M-$41.68M$115.79M$223.80M Nightstar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NITENightstar TherapeuticsN/A$29.67-0.4%N/A+16.8%$995.13MN/A-23.5547DNLIDenali Therapeutics4.5994 of 5 stars$25.79+3.2%$38.90+50.8%+25.9%$3.71B$330.53M-9.06364Positive NewsSRRKScholar Rock3.9441 of 5 stars$38.02-4.7%$40.43+6.3%+192.8%$3.56B$33.19M-16.98140IBRXImmunityBio1.9509 of 5 stars$4.95-1.8%$17.38+251.0%+20.6%$3.45B$7.33M-5.40590KYMRKymera Therapeutics2.2385 of 5 stars$48.25+3.0%$53.40+10.7%+125.9%$3.12B$87.56M-20.02170Analyst UpgradeNews CoveragePositive NewsGap UpSWTXSpringWorks Therapeutics1.9091 of 5 stars$41.72+0.6%$69.50+66.6%+33.4%$3.10B$135.49M-10.69305Positive NewsTWSTTwist Bioscience3.4732 of 5 stars$50.29+2.3%$51.00+1.4%+104.2%$2.99B$312.97M-13.66990Positive NewsVCELVericel1.4282 of 5 stars$58.76+1.1%$59.71+1.6%+63.5%$2.90B$197.52M979.16300Insider TradeIOVAIovance Biotherapeutics4.408 of 5 stars$9.12-2.1%$22.33+144.9%+39.5%$2.78B$1.19M-6.25500Short Interest ↓CGONCG Oncology2.0463 of 5 stars$35.58+2.4%$63.88+79.5%N/A$2.41B$684,000.000.0061News CoveragePositive NewsBEAMBeam Therapeutics3.4659 of 5 stars$28.32+3.5%$44.91+58.6%-12.1%$2.35B$377.71M-15.55461Positive News Related Companies and Tools Related Companies DNLI Alternatives SRRK Alternatives IBRX Alternatives KYMR Alternatives SWTX Alternatives TWST Alternatives VCEL Alternatives IOVA Alternatives CGON Alternatives BEAM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NITE) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHas World War III already started?As global tensions are rising, so does the potential of direct conflict between the US and China. That's wh...Behind the Markets | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
